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ABSTRACT
MARGARET ANN STREET: Modification of HIV-1 Protease Inhibitor Pharmacophore
to Assess Anti-Malarial Properties
(Under the direction of John Rimoldi)

For years, the human immunodeficiency virus type 1 (HIV-1) and malarial
parasites have both been prevalent in sub-Saharan Africa. Coinfections of HIV-1 and
malaria are common in areas of geographic overlap as both infections seem to increase
the severity of the other. HIV-1 treatments have shown to decrease the Plasmodium
infections resulting in a lower malarial incidence. HIV-1 protease inhibitors target a
crucial step in the life cycle required for viral maturation and have demonstrated a lower
level of resistance compared with other therapies. Recent studies have shown the
treatment of HIV-1 with protease inhibitors has resulted in inhibitory effects against the
Plasmodium falciparum malaria parasite. With growing resistance to current anti-malarial
drugs, the need for new compounds is crucial. In an effort to identify the key functional
group in protease inhibitors responsible for malaria inhibition, the lopinavir analogs were
designed around blocking the HIV-1 activity. The secondary alcohol required for HIV-1
activity was modified in each of the designed compounds in an effort to isolate the
malarial inhibition. The compounds were submitted for biological evaluation in a
malarial inhibition assay against the chloroquine-sensitive and chloroquine-resistant
strains of P. falciparum. The modifications of the secondary alcohol within the protease
inhibitor pharmacophore resulted in a decreased potency against the malaria protozoan,
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demonstrating a need for further research on how the protease inhibitor targets P.
falciparum.
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INTRODUCTION

The human immunodeficiency virus type-1 (HIV-1) is a retrovirus that infects the
cluster of differentiation 4 positive (CD4+) T-lymphocytes (T-cells) of the immune
system. This impairs the immune system's ability to fight off infections leaving people
living with HIV-1 vulnerable to other infections and diseases.1 Infections associated with
immunodeficiency are known as opportunistic infections as they take advantage of the
weakened immune system. HIV-1 is a slowly progressing disease that continues to
damage the immune system from the time of infection until the presence of a high viral
load and opportunistic infections eventually lead to acquired immunodeficiency
syndrome (AIDS).2
Many were skeptical regarding the high HIV-1 prevalence in African countries as
the World Health Organization (WHO) prevalence maps for HIV-1 in the early 1990s
showed very low levels in south Africa creating a lack of urgency. The 1990s soon
became characterized by an HIV-1 epidemic with very high morbidity and over half of
adult mortalities attributable to HIV-1.3 At the end of 2017, more than thirty-six million
people were living with HIV-1 and AIDS worldwide. The WHO African region, shown
in Figure 1, remains the most severely affected with 1 in 25 adults living with HIV-1.4

1

Figure 1: Prevalence of HIV-1 among adults ages 15-49 in 2017 by WHO region4

Development of HIV Protease Inhibitors
In the 1990s, few antiretrovirals were available so the primary management for
HIV-1 was largely based on proper prophylaxis. Drug development focused on targeting
each stage of the HIV-1 retroviral life cycle, shown in Figure 2. As more antiretrovirals
were developed, the standard of care progressed from monotherapy to combination
therapy.5 The most current and most effective AIDS therapy is a form of combination
therapy known as highly active antiretroviral therapy (HAART). The HAART combines
the use of an HIV-1 protease inhibitor, reverse transcriptase inhibitor, and/or an integrase
inhibitor. Protease inhibitors have proven to be one of the most important components in
combination therapy due to the lower level of resistance compared with other therapies.6
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Figure 2: Drug Targets within the HIV Life Cycle7

HIV-1 proteases are essential in creating mature infectious viral particles. The HIV1 protease is an aspartyl protease meaning it contains an aspartic acid in the active site.
The protease is assembled in a symmetric homodimer with two identical subunits of
ninety-nine amino acids.8 The protease peptides have a superimposable secondary
structure that creates a pocket designed to fit the substrate binding regions. This pocket
allows the protease to recognize the skewed shape of the peptide rather than targeting a
specific amino acid sequence. The protease active site is covered by two flexible ß-flaps
that must be opened to allow the substrate to enter. The polyprotein precursor is cleaved
3

and digested into protease, reverse transcriptase, and integrase. The protease inhibitor
complexes with the HIV-1 protease, shown in Figure 3, to block the active site preventing
viral maturation. The secondary hydroxyl group of the inhibitor interacts with the
protease via hydrogen bonding with the carboxyl group of the active site aspartic
residues.6

Figure 3: HIV-1 protease structure in complex with lopinavir
From PDB 6DJ19

The pharmacophore of a molecule is the spatial arrangement critical for interactions
in a specific binding site for a target receptor. Pharmacophores are often considered the
largest common feature shared among a set of active molecules.10 The majority of FDA
approved HIV-1 protease inhibitors contain the hydroxyethylamine pharmacophore,
highlighted in blue in Figure 4, designed to mimic the substrate transition state in order to
interact with the protease active site. The secondary hydroxyl group of the
pharmacophore is crucial for its interaction with the carboxyl group of the HIV-1
4

protease active site.6 If the hydroxyethylamine pharmacophore is removed or
substantially altered, the resulting ligands will not interact with the binding site of the
target receptor therefore eliminating the inhibitory effects.

Figure 4: Nine FDA approved HIV-1 protease inhibitors11

Interaction of HIV-1 and Malaria
HIV-1 and malaria have proven to be two of the deadliest diseases, both of which
are prevalent in sub-Saharan Africa. According to statistics from 2013, sub-Saharan
Africa contains only 12% of the global population yet is burdened with 71% of the global
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HIV-1 infection. Although HIV-1 infection trends in sub-Saharan are declining, almost
80% of those living with HIV-1 worldwide are located in southern and eastern Africa.12
Co-infections with HIV-1 and malaria have become common in sub-Saharan Africa
with each enhancing the other's severity. The geographic overlap between HIV-1 and
Plasmodium species has contributed to the spread of both diseases and led to an increase
in coinfections.13 HIV-1 infected individuals are more susceptible to malaria infections
due to immune deficiency, which should lead to an increase in the frequency of
coinfections with malaria.14 Malaria infections create an ideal environment for HIV-1
replication, accelerating the progression of HIV-1. Malaria infections increase CD4+ Tcell activation to induce a strong inflammatory immune response. With this synergistic
effect enhancing the harm to the patient, development of treatment options for coendemic settings are crucial and the effectiveness of antiretroviral drugs in malarial
settings needs to be tested.15
Current treatment options for malaria control are precarious, so recent measures
have been taken to develop new or to repurpose existing drugs for valuable interventions
in controlling the spread of infections. All recommended drug combinations for HIV-1
treatment have been shown to significantly decrease Plasmodium infections with protease
inhibitors resulting in the lowest clinical malaria incidence.13 Protease inhibitors are
strong antiretrovirals with effective HIV-1 treatment but have also demonstrated effective
in vitro activity against some malarial strains of Plasmodium falciparum.15 According to
a study performed in 2012, the lopinavir-ritonavir combination drug decreased the risk
for malaria infections by roughly forty percent.16 The protease inhibitor, lopinavir, is
prepared as a combination formula with ritonavir. Ritonavir is a strong enzyme inhibitor
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that increases with bioavailability of lopinavir, making lopinavir more effective against
viral infections.17 Of the protease inhibitors tested, lopinavir, shown in Figure 5, was the
most potent antimalarial inhibitor, demonstrating a half maximal inhibitory concentration
(IC50) nearly tenfold below the trough blood concentration achieved with standard
dosing.18 The inhibitory concentration results indicated lopinavir was one of the most
promising for antimalarial development, which was the reason lopinavir was chosen for
this project.

(1)

Figure 5: Structure and IUPAC name of Lopinavir
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MATERIALS AND METHODS
General Methods
Each reaction was monitored for consumption of starting material or product
formation using thin-layer chromatography (TLC) techniques and detection with
ultraviolet (UV) light at 254 nM (lopinavir is UV active due to the presence of aromatic
rings). The TLC plates were stained with phosphomolybdic acid (PMA) or potassium
permanganate and heated to aid visualization of the compound.
All commercially available starting materials and reagents were purchased at the
highest commercial quality and used without further purification unless otherwise noted.
With many of the reagents being sensitive to moisture, all of the reactions were
performed under standard anhydrous conditions. Standard anhydrous conditions indicate
the reactions were performed in flame-dried glassware evacuated and cleared with an
inert blanket of argon while using commercially available anhydrous solvents. Three
analogs, shown in Figure 6, were synthesized from lopinavir using procedures derived
from immunochemically equivalent compounds.19 Lopinavir was deprotonated using
sodium hydride or trichloroacetyl isocyanate and the appropriate alkylating agent was
added to synthesize the desired analog.
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(2)

(3)

(4)
Figure 6: Synthesized Analogs of Lopinavir

Molecular weight analysis was performed using a Waters Micromass Quattro
Micro mass spectrometer with either positive (ESI+) or negative (ESI-) electrospray
ionization. A Bruker 400 MHz Avance Nuclear Magnetic Resonance (NMR)
spectrometer was used in acquiring the proton (1H) and carbon (13C) NMR spectral data,
which was then processed using MNova (MestReNova) software. A Teledyne ISCO
CombiFlash Rf+ PurIon was used to conduct preparative high performance liquid
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chromatography (HPLC) in separating and purifying the desired compounds from the
product mixture. The desired compounds were assessed for inhibition against the
Plasmodium falciparum protozoan using the antimalarial assay conducted by the National
Center for Natural Product Research (NCNPR) at the University of Mississippi.

Experimental Methods
Lopinavir Carbamate
Under standard anhydrous conditions,
commercially available lopinavir (100 mg,
0.159 mmol) was dissolved in
dichloromethane (1 mL) and cooled in an
(2)

ice bath to 0 ºC. Trichloroacetyl

isocyanate (40 µL, 0.318 mmol) was slowly added to the solution. The reaction mixture
was allowed to reach room temperature as it stirred for four hours. The crude product was
concentrated under reduced pressure to produce lopinavir-o-trichloroacetylcarbamate.
Potassium carbonate (455 mg, 3.3 mmol), methanol (4.5 mL), and water (1.5 mL) were
added to the crude product at 0 ºC. The reaction mixture was allowed to stir at 0 ºC for
one hour and at room temperature for eighteen hours. The mixture was concentrated
under reduced pressure. Chloroform (100 mL) and water (30 mL) were added to the
residue. The mixture was transferred to a separatory funnel and extracted 3 times with 20
mL of chloroform. The organic layers were combined and dried over magnesium sulfate.
The organic layers were concentrated in a vacuum to give 115 mg of crude product.
Purification of 50 mg of the crude product was accomplished using RP-HPLC with a
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mobile phase consisting of a water-acetonitrile gradient. The mass of each fraction was
analyzed, and the product fraction was lyophilized to remove water. From the 50 mg of
crude material, 24 mg of the desired product was obtained (48% yield). MS (ESI+) m/z =
694.55 [M+Na]+ 1H NMR (500 MHz, Methanol-d4) δ 7.81 (d, J = 9.2 Hz, 1H), 7.36 –
7.19 (m, 9H), 7.21 – 7.13 (m, 1H), 7.01 (d, J = 7.4 Hz, 2H), 6.98 – 6.91 (m, 1H), 5.02
(ddd, J = 8.1, 6.2, 2.3 Hz, 1H), 4.84 (s, 1H), 4.45 (dt, J = 10.1, 5.2 Hz, 1H), 4.33 (d, J =
11.2 Hz, 1H), 4.15 (d, J = 14.9 Hz, 1H), 4.07 (d, J = 14.9 Hz, 1H), 3.21 – 3.10 (m, 2H),
3.05 (ddd, J = 11.5, 7.0, 4.0 Hz, 1H), 2.99 – 2.77 (m, 4H), 2.59 (dd, J = 13.6, 9.8 Hz,
1H), 2.18 (s, 6H), 2.17 (d, J = 10.1 Hz, 1H), 1.89 – 1.75 (m, 2H), 1.73 – 1.64 (m, 1H),
1.50 (dt, J = 11.2, 6.3 Hz, 1H), 0.91 (d, J = 6.5 Hz, 3H), 0.84 (d, J = 6.7 Hz, 3H). 13C
NMR (126 MHz, MeOD) δ 170.38, 170.29, 169.61, 157.73, 157.11, 154.35, 138.50,
137.82, 130.32, 129.21, 129.05, 128.70, 128.01, 127.93, 126.16, 125.73, 124.44, 72.99,
69.55, 62.59, 51.70, 51.62, 48.16, 47.99, 47.82, 47.65, 47.48, 47.31, 47.14, 40.48, 40.17,
39.40, 37.84, 37.49, 25.53, 21.17, 18.82, 17.60, 15.05.

Lopinavir Methyl Acetate
Under standard anhydrous conditions,
commercially available lopinavir (80 mg,
0.127 mmol) was dissolved in THF at
room temperature. Sodium hydride, 60%
in oil, (24 mg) was added and the mixture

(3)

stirred for one hour at room temperature. Methyl bromoacetate was added and the
reaction stirred at room temperature for twenty-four hours. The mixture was quenched
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with a 50mM phosphate buffer (sodium and potassium) and stirred at room temperature
for one hour. The reaction mixture was transferred to a separatory funnel and extracted 4
times with 10 mL of ethyl acetate. The organic layers were combined and dried with
magnesium sulfate. The organic layers were concentrated in a vacuum to give 100 mg of
crude product. The product was then purified using preparative TLC using 5% isopropyl
alcohol in chloroform. MS (ESI+) m/z = 724.56 [M+Na]+.1H NMR (400 MHz,
Methanol-d4) δ 7.31 (dd, J = 17.5, 7.2 Hz, 5H), 7.25 (d, J = 4.4 Hz, 5H), 7.23 – 7.16 (m,
1H), 7.05 – 6.90 (m, 5H), 4.45 (s, 2H), 4.29 (dd, J = 28.5, 13.7 Hz, 3H), 4.19 – 4.11 (m,
2H), 4.07 (d, J = 14.8 Hz, 1H), 3.78 (s, 3H), 3.66 (s, 2H), 3.55 (d, J = 9.5 Hz, 1H), 3.17
(s, 2H), 3.15 – 3.01 (m, 1H), 3.04 (s, 1H), 2.97 (dd, J = 13.9, 4.9 Hz, 1H), 2.87 – 2.79 (m,
3H), 2.70 – 2.59 (m, 1H), 2.37 – 2.25 (m, 1H), 2.19 (d, J = 11.9 Hz, 5H), 2.19 (s, 6H),
1.92 (s, 0H), 1.84 (t, J = 12.6 Hz, 1H), 1.72 (d, J = 11.3 Hz, 1H), 1.55 (s, 15H), 1.32 (d, J
= 6.8 Hz, 7H), 0.96 – 0.88 (m, 1H), 0.85 (dd, J = 6.7, 2.5 Hz, 7H).
Lopinavir Methyl Acetic Acid
Under standard anhydrous conditions,
commercially available lopinavir (80 mg,
0.127 mmol) was dissolved in
tetrahydrofuran (3 mL) at room
(4)
temperature. Sodium hydride, 60% in oil,
(19 mg) was added to the solution. The reaction stirred for one hour at room temperature.
Methyl bromoacetate was added and the reaction mixture continued to stir at room
temperature for ninety-six hours. Potassium phosphate was added followed by lithium
hydroxide monohydrate and the reaction mixture stirred at room temperature for an
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additional ninety-six hours. The reaction mixture was concentrated under pressure.
Approximately six drops of 20% phosphoric acid were added to acidify the aqueous
residue to a pH of 5-6 and extracted 5 times with 15 mL of chloroform. The organic
layers were combined and dried over magnesium sulfate and concentrated in a vacuum to
give 107 mg of crude product. The crude product was purified using preparative TLC
using isopropyl alcohol, trifluoroacetic acid, and chloroform. MS (ESI-) m/z = 685.42
[M-H]-

Anti-Malarial Bioassay
The antimalarial screening was completed by the National Center for Natural
Products at the University of Mississippi. The NCNPR antimalarial screening was funded
by United States Department of Agriculture, Agricultural Research Service Specific
Cooperative Agreement, Grant Number 58-6408-1-603. The antimalarial screening tests
a sample’s ability to inhibit the chloroquine sensitive or chloroquine resistant
Plasmodium falciparum protozoan. The primary screen tests crude extracts at 15,867
ng/mL against the D6 P. falciparum strain. The percent inhibitions are calculated relative
to negative and positive controls. If the extract shows greater than fifty percent inhibition,
it proceeds to the secondary assay.
In the secondary assay, the pure column fractions were dissolved to a
concentration of 2 mg/mL. The samples were tested to determine the half maximal
inhibitory concentration (IC50) for both the chloroquine-sensitive (D6) and the
chloroquine-resistant (W2) clones of P. falciparum. Analogues were evaluated for in
vitro cytotoxicity against mammalian kidney cell line (VERO) up to a concentration of
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4760 ng/mL via a neutral red assay. The IC50 is reported as the test concentration in
nanograms per milliliter that provides a fifty percent inhibition of the protozoan relative
to negative and positive controls. The positive controls in this assay were the antimalarial
drug controls chloroquine and artemisinin. The selectivity index (SI) is calculated as a
ratio of VERO IC50 to the IC50 of either D6 or W2 P. falciparum strain. The VERO IC50
is the concentration at which fifty percent of the viable cells die due to cytotoxicity. A
high SI is favorable as the compound will have a higher selectivity towards the pathogen
compared to the host.
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RESULTS AND DISCUSSION

Three target analogues were successfully synthesized from lopinavir, which include
lopinavir carbamate, lopinavir methyl acetate, and lopinavir methyl acetic acid. For each
reaction, the secondary alcohol of lopinavir was targeted for deprotonation in order to add
the desired group to the product molecule. Lopinavir (1) was deprotonated using sodium
hydride or trichloroacetyl isocyanate and the appropriate alkylating agent was added to
form the carbamate (2), methyl acetate (3) and methyl acetic acid (4) analogs. The
structures of the final products were confirmed using MS and NMR spectrometry.
The hydroxylethylamine pharmacophore was modified to block the antiretroviral
activity in an attempt to isolate the antimalarial activity for amplification. If the analogs
were submitted for HIV-1 assays, the elimination of the hydroxylethylamine
pharmacophore would likely result in the analogs being devoid of HIV-1 inhibitory
activity. With the antiretroviral pharmacophore inhibited, the compounds were subjected
to a biological assay to determine the concentration needed to acquire antimalarial
activity. The results from the biological evaluation screening, shown in Table 1, indicate
the modification of the hydroxyl group decreases the inhibitory effects against the
malaria Plasmodium falciparum. This proves the secondary hydroxyl group is not only
necessary for the antiretroviral activity but also for the antimalarial activity. The
unmodified lopinavir demonstrated the greatest potency against both the D6 and W2
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strains at concentrations of 4.26 µM and 2.1 µM, respectively. Previous in vitro studies
have the IC50 of lopinavir against the W2 strain as being 2.7 µM, which is relatively high
compared with its HIV activity of 0.005 µM.20 The modification with the methyl acetate
and methyl acetic acid demonstrated a decrease in potency for the P. falciparum D6 and
W2 strains as the concentration needed for inhibition exceeded the limitations of the
assay. Although the IC50 increased for the methyl acetate and methyl acetic acid, the
analogs likely still have sufficient antimalarial activity compared to other protease
inhibitors. Lopinavir has a relatively high activity against malaria compared with other
HIV-1 protease inhibitors, which average at 17µM.20
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P. falciparum

P. falciparum

P. falciparum

P. falciparum

D6 IC50

D6 SI

W2 IC50

W2 SI

O

2681

>1.8

1324.3

>3.6

O

>4760

1

3563.1

>1.3

>4760

1

>4760

1

>4760

1

>4760

1

Compound

O

OH
H
N
N
H

N

O

O

HN

(1)
H 2N
O
O

O
H
N
N
H

N

O

O

HN

(2)

(3)

(4)
Table 1. Antimalarial screening results from NCNPR. All concentrations are in
nanograms per milliliter.

The high SIs calculated for lopinavir at 1.8 and 3.8 demonstrate an achievable
inhibitory concentration with minimal cytotoxicity effects. Although the screening was
limited by the concentration range, the values indicate lopinavir methyl acetate and
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lopinavir methyl acetic acid would require at least a four-fold increase in the drug
concentration compared with lopinavir.
All three of the synthesized analogs are increased in size compared with lopinavir
due to the addition of the larger functional groups. This increase in size could be
interfering with the interaction of the inhibitor and malaria, causing a decrease in
inhibitory activity. The change in the hydroxyl group decreases hydrogen bonding which
likely interferes with the inhibitory interactions with malaria. The lopinavir carbamate
analog resulted in a better inhibitory concentration compared with the lopinavir acetate
and lopinavir acetic acid, indicating hydrogen bonding is a crucial interaction.
The biological screening is consistent in measuring the potency of the compound
toward the particular malarial strain without disturbance from other variables, such as cell
membrane permeability. Each of the analogues should have had the necessary lipophilic
character, which is shown in Table 2, to penetrate the cell membrane. With this variable
eliminated, the results from the screening are able to focus exclusively on the inhibitory
effects for the malarial strains.

18

Compound

O

Molecular Weight

ClogP

O

628.81

6.0946

O

671.84

6.127

700.88

6.91

686.85

6.0379

OH
H
N
N
H

N

O

O

HN

(1)
H 2N
O
O

O
H
N
N
H

N

O

O

HN

(2)

(3)

(4)
Table 2. Chemical properties of lopinavir and synthesized analogs.
ClogP estimations from ChemDraw.

Based on the malarial inhibition data, it can be concluded that the secondary
hydroxyl group is required for malarial inhibition as modification of this functional group
increased the concentration needed for fifty percent inhibition. This indicates the
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secondary hydroxy group in the pharmacophore of the protease inhibitor contributes to
both the antiretroviral activity and the antimalarial activity. If HIV-1 assay data was
available for these compounds, it would most likely show the analogs devoid of HIV-1
inhibitory activity. Additional research is needed to validate the importance of the
hydrogen bonding in malarial inhibition. Analogs need to be synthesized with functional
groups similar in size to the hydroxyl to explore trends for a lack of hydrogen bonding
and for an increase in hydrogen bonding. In this research, only the D6 and W2 strains of
malaria were assayed; however, investigation into the most prominent strains in subSaharan Africa is needed. Research is also needed to determine the protease inhibitor’s
mechanism of action for inhibiting the varying strains of P. falciparum.
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